Skin biopsy market seen reaching $2.74B by 2030

The skin biopsy market is projected to grow from $1.86 billion in 2025 to $2.74 billion by 2030, driven by rising skin cancer cases, more dermatology clinics and broader use of AI-enabled diagnostics. North America leads the market now, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Skin biopsy is a core diagnostic procedure for infections, inflammatory diseases and skin cancers, so market growth tracks broader demand for earlier and more precise dermatology care. - Rising healthcare spending is expanding access to advanced diagnostic tools and dermatology services. - Growth in the market points to more use of minimally invasive testing, AI-supported pathology and outpatient diagnostics.

What happened: - The Business Research Company said the global skin biopsy market was valued at $1.86 billion in 2025. - The market is projected to reach $2.02 billion in 2026 and $2.74 billion by 2030. - The report forecasts an 8.3% CAGR from 2025 to 2026 and an 8.0% CAGR through 2030. - The company released its Skin Biopsy Market Report 2026, covering market size, trends and a global forecast for 2026-2035.

The details: - Market growth during the historical period has been driven by more skin cancer cases, a larger number of dermatology clinics, wider use of outpatient diagnostic procedures, greater availability of biopsy instruments and higher awareness of early diagnosis. - Future growth is expected to come from rising melanoma incidence, AI-enhanced diagnostic tools, tele-dermatology expansion, an aging population and higher demand for cosmetic dermatology procedures. - Key trends include minimally invasive biopsy methods, broader diagnostic advances in dermatology, preference for punch and shave biopsy techniques, and AI integration in pathology for improved accuracy. - North America is the largest market for skin biopsy services in 2025. - Asia-Pacific is projected to post the fastest growth in the coming years. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report edition adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The report is available as a free sample through the sample report. - The full report is available at the full skin biopsy market report.

Between the lines: - The forecast suggests dermatology diagnostics are moving toward faster, less invasive and more technology-driven workflows. - North America’s lead signals a mature market with strong infrastructure, while Asia-Pacific’s growth points to unmet demand and expanding healthcare access. - The healthcare-spending tailwind suggests this market benefits from broader investment in medical diagnostics, not just skin-specific demand.

What's next: - The market’s next phase will likely be shaped by how quickly providers adopt AI tools, tele-dermatology and minimally invasive biopsy techniques. - Faster growth in Asia-Pacific could shift competitive focus toward markets investing heavily in dermatology capacity. - Ongoing expansion in healthcare budgets should continue to support demand for skin biopsy instruments and services.

The bottom line: - Skin biopsy is set for steady global growth as cancer detection, digital diagnostics and broader access to care push the market higher through 2030.